10.05.23
DelNova has entered a partnership with Pace Life Sciences to serve as its contract development and manufacturing organization. The partnership will support clinical development of DelNova’s lead candidate ReViVox for the rescue of undesirable outcomes which may arise from a botulinum neurotoxin (BoNT) treatment such as Botox. Pace Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, and regulatory compliance, services to the biopharmaceutical industries.
Pace Life Sciences offers the support needed to complete the IND (investigational new drug)- enabling research for the future FDA submissions including formulation, kinetics, and stability.
Also, through its partnership with Pace Life Sciences, DelNova will now have the capacity to manufacture small GMP batches of drug product for clinical studies. Pace has facilities across the U.S., including a specialized CDMO facility in San Diego with expertise in complex drug delivery, formulation, sterile fill-finish GMP manufacturing.
Currently there is no product available that can reverse unwanted paralysis induced by BoNTs. ReViVox has the potential to be the first in class product to address this unmet medical need.
Pace Life Sciences offers the support needed to complete the IND (investigational new drug)- enabling research for the future FDA submissions including formulation, kinetics, and stability.
Also, through its partnership with Pace Life Sciences, DelNova will now have the capacity to manufacture small GMP batches of drug product for clinical studies. Pace has facilities across the U.S., including a specialized CDMO facility in San Diego with expertise in complex drug delivery, formulation, sterile fill-finish GMP manufacturing.
Currently there is no product available that can reverse unwanted paralysis induced by BoNTs. ReViVox has the potential to be the first in class product to address this unmet medical need.